Clinical trials: Patient Experience
Macular Degeneration, Age-related Macular Degeneration
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.
- Conditions
- Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration
- Trial name
- MACULA (NCT01245387)
- Testing
- Pegaptanib
- Volunteers
- 1,001 people
- Sponsor
- Pfizer
Asthma
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
The purpose of this study is to investigate the effectiveness of Alvesco® (Ciclesonide) compared with usual asthma care in the primary care setting.
- Trial name
- NCT00404547
- Testing
- Ciclesonide, Usual Care Inhaled Glucocorticosteroids
- Where
- 186 sites in Canada
- Volunteers
- 1,121 people
- Sponsor
- AstraZeneca
Myopia
A Multi-Center Investigation of Patient Acceptability of OPTI-FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
The purpose of this study was to demonstrate that current successful fulltime daily wear soft contact lens wearers using competitive multi-purpose solutions will note improved comfort when using OPTI-FREE RepleniSH®.
- Trial name
- NCT00772707
- Testing
- Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH), Contact Lenses
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Arthritis, Rheumatoid
Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe
This is an open-label, phase II study of BI 695501 to assess handling experience of patients with Rheumatoid Arthritis using an autoinjector.
- Trial name
- NCT02636907
- Testing
- BI 695501 Autoinjector, BI 695501 Prefilled syringe
- Where
- 19 sites in United States, Poland
- Volunteers
- 77 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients
- Trial name
- NCT00879411
- Testing
- Micardis
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
The fixed combination of verapamil SR/trandolapril (Tarka®) is an effective, well-tolerated therapy for the treatment of essential hypertension in those who require more than one agent to achieve optimal blood pressure (BP)…
- Trial name
- NCT01127139
- Where
- 134 sites in Czechia
- Volunteers
- 3,828 people
- Sponsor
- Abbott
Type 2 Diabetes Mellitus (T2DM)
Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
This study was aimed to achieve of long-term weight loss in T2DM patients by use of comprehensive lifestyle changes program, providing patients with structured diet, exercise plan, group behavioral support and group education.
- Trial name
- NCT02670928
- Testing
- Lifestyle intervention
- Where
- 2 sites in Russia
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice
The general aim of this non-interventional study is to assess the safety and efficacy of pramipexole extended release in patients with Parkinson's disease in routine clinical practice.
- Trial name
- NCT01061567
- Where
- 284 sites in Austria, Estonia and 5 more
- Volunteers
- 1,814 people
- Sponsor
- Boehringer Ingelheim
Peripheral Arterial Disease
Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
The PID-PAB study aims to test the efficacy of the European Guidelines on Cardiovascular Disease Prevention in patients with peripheral arterial disease.
- Trial name
- PID-PAB (NCT00761969)
- Testing
- Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice
- Where
- Slovenia
- Volunteers
- 1,455 people, healthy volunteers welcome
- Sponsor
- KRKA
Chronic Kidney Failure, Secondary Hyperparathyroidism
Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.
- Trial name
- PROTECT (NCT01083186)
- Where
- 24 sites in Greece
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.
The aim of this study is to describe and evaluate clinical outcomes, treatment lines, and to identify the key characteristics of the patients treated with tofacitinib.
- Trial name
- NCT05082428
- Where
- Finland
- Volunteers
- 252 people
- Sponsor
- Pfizer
Osteoporosis, Postmenopausal
Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice
The objective of this prospective, observational study in Czech Republic and Slovakia is to describe per country the characteristics of women treated with denosumab in routine clinical practice and the clinical management of…
- Trial name
- NCT01652690
- Testing
- Denosumab
- Where
- 29 sites in Czechia, Slovakia
- Volunteers
- 600 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Pulmonary Disease, Chronic Obstructive
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual…
- Trial name
- NCT03467425
- Testing
- FF/UMEC/VI, Inhaled Corticosteroid, LAMA
- Where
- 143 sites in Germany, Netherlands and 3 more
- Volunteers
- 3,109 people
- Sponsor
- GlaxoSmithKline
Candidiasis
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.
- Trial name
- NCT01202253
- Testing
- anidulafungin
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish…
- Trial name
- NCT03281200
- Testing
- L - Antineoplastic and immunomodulating agents, L01 - Antineoplastic agents, L01X - Other antineoplastic agents
- Where
- Spain
- Volunteers
- 172 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria
This is a prospective non-interventional observational study to evaluate the treatment of moderately active RA patients in every day clinical practice in Austria. Patients will be observed over 52 weeks.
- Trial name
- NCT01877239
- Testing
- non-intervention
- Where
- 10 sites in Austria
- Volunteers
- 111 people
- Sponsor
- Pfizer